The SRG rat demonstrates robust immune-system humanization with peripheral blood mononuclear cells, the huPBMC-SRG rat™. First published in Hera’s 2017 AACR-EORTC-NCI Molecular Targets poster Novel immunodeficient rat models offers a unique platform for drug efficacy studies in human tumor xenografts. Humanized SRG rats may have advantages in immuno-oncology, in particular for tumor models with low take-rates in mice.
Hera is now providing pre-implanted huPBMC-SRG rats as well as immuno-oncology studies in hu-PBMC-SRG rats, NSG mice and NOG mice. Please see our Immuno-oncology services page for more information.